Ibogaine for PTSD: What the Stanford Study Found, and Its Limits

PTSD is not a veteran’s condition. That framing has dominated public understanding for years — understandably, given the scale of combat trauma and the research focus that followed. But the data on who actually lives with PTSD tells a different story: sexual assault survivors, childhood abuse survivors, people who have been through medical crises, first responders, accident victims, and anyone who has experienced events their nervous system filed as catastrophic.

This page covers what the Stanford study found, what that evidence does and does not establish, and who ibogaine plausibly suits.

What Did the Stanford Ibogaine Study Find for PTSD?

One month after a single magnesium–ibogaine treatment, 30 special-operations veterans averaged an 88% reduction in PTSD severity (CAPS-5), with large drops in depression and anxiety too. It was an open-label study with no control group: a strong signal, not proof.

Published in Nature Medicine on 5 January 2024, the Cherian et al. study enrolled 30 male Special Operations Forces veterans with a history of predominantly mild TBI and repeated blast or combat exposure. Twenty-three of the 30 met the diagnostic criteria for PTSD at baseline, 15 for major depression and 14 for an anxiety disorder.

The protocol has a name the coverage usually leaves out: MISTIC — Magnesium–Ibogaine: the Stanford Traumatic Injury to the CNS protocol. Magnesium sulfate is given intravenously before and about 12 hours after the ibogaine, because magnesium shortens the Q–T interval and may offset ibogaine’s best-documented cardiac risk. After a single oral ibogaine dose (12.1 ± 1.2 mg/kg) at Ambio Life Sciences in Tijuana, at one month:

Source: Cherian et al., Nature Medicine, 2024. Open-label, n=30, all male, no control group, one-month follow-up.

The study was run by Stanford School of Medicine’s Brain Stimulation Lab with Palo Alto University and the VA Palo Alto Health Care System; treatment itself took place at Ambio Life Sciences in Mexico, and travel was funded by the veterans’ non-profit VETS, Inc. What the paper is careful to say, and most coverage is not: this was an open-label observational study with no control group and no placebo, all 30 participants were male, the TBI was predominantly mild, and the follow-up ran to one month (a 12-month follow-up has since been published; see below). The authors state plainly that they “cannot exclude the possibility that the therapeutic benefits were a result of expectancy” and that controlled trials are needed. Several participants had symptoms return between the immediate and one-month assessments — though even those with the most prominent relapses still showed more than 30% improvement against baseline, and no participant got worse.

Day-to-day functioning improved too: the WHODAS total score fell from 30.2 (mild-to-moderate disability) at baseline to 5.1 (no disability) at one month. The paper does not report a single headline percentage for cognition, and we will not invent one. What it does report, from a full neuropsychological battery, is significant gains in processing speed (d=0.97–1.34) and executive function (d=0.31–1.22), with improvement or no change on every domain tested and no decline anywhere. That matters for a compound once suspected of cerebellar toxicity. For the full background on the study, see our write-up of the Stanford ibogaine study.

Did the PTSD improvement last a year?

Largely, yes. In the 12-month follow-up, PTSD, depression, anxiety and disability scores stayed well below baseline. Of veterans in PTSD remission right after treatment, an estimated 84% were still in remission a year later.

The same Stanford team published the follow-up in Translational Psychiatry on 12 August 2026 (Faerman, Lissemore et al.). Of the 30 veterans treated, 25 completed the 12-month assessments, with check-ins at 3, 6, 9 and 12 months. Effect sizes at 12 months were still large (Cohen’s d of 2.18 or more), and the estimated probability of staying in remission was 84% for PTSD, 66% for depression and 61% for anxiety.

The new limit to know about: most participants used other psychedelics or started other treatments during the year, so the paper cannot separate ibogaine’s lasting effect from what came after it. It is still a naturalistic cohort with no control group, and the authors call for randomized controlled trials next.

Who the Research Actually Studied — and Who It Did Not

This is the most important caveat on the page, and it is the one most often left out. The headline figures people quote for ibogaine and PTSD come overwhelmingly from one population: male US special operations veterans, most with a history of repeated blast exposure and traumatic brain injury, treated at clinics in Mexico and assessed without a control group.

That is a specific group of people with a specific injury profile. It is not the same as a civilian with PTSD following sexual assault, a survivor of childhood abuse, a paramedic with cumulative occupational trauma, or someone whose trauma is ongoing rather than historic. Those groups have not been studied in this context in any comparable way.

This does not mean ibogaine is unhelpful for them. It means nobody currently knows, and the confident claims circulating online are extrapolating well beyond what was measured. If you belong to one of those groups, the honest position is that you would be making a decision on weaker evidence than the numbers suggest — and you deserve to be told that before you spend the money, not after.

What the Evidence Can and Cannot Establish

Open-label and observational studies — which is what almost all of the ibogaine PTSD research is — can show that something is worth investigating further. They cannot establish that it works.

The reason is not pedantry. In an open-label study everyone knows what they received, there is no comparison group, and participants have usually travelled a long way at considerable expense to take part. Expectation alone produces substantial improvement in trauma symptoms, and self-reported measures are particularly sensitive to it. Add the natural tendency of symptoms to fluctuate, and a study designed this way will tend to show improvement whether or not the drug is doing the work.

The signal in the ibogaine data is large enough and consistent enough that serious researchers consider it worth the cost of a proper trial. That is a real and meaningful statement. It is simply a different statement from “ibogaine treats PTSD,” and the gap between the two is where most of the misleading marketing lives.

How It Sits Alongside the Trauma Treatments That Do Have Trial Evidence

Several trauma therapies have been tested in randomised controlled trials and are recommended as first-line treatment by major clinical bodies — among them cognitive processing therapy, prolonged exposure, and EMDR. They are not quick, they are demanding, and they do not work for everyone. But the evidence behind them is of a kind ibogaine does not yet have.

Anyone weighing ibogaine for PTSD should be clear about where they are in relation to those options. There is a real difference between someone who has completed a course of trauma-focused therapy without adequate benefit and someone who has not tried one because the waiting list was long or the first session was hard. Both are understandable positions. Only the first is a case where the evidence gap is a reasonable trade.

It is also worth knowing that ibogaine is not a substitute for that work so much as, at best, a possible opening for it. The people who report the most durable change are generally those who had trauma-focused support arranged for the period afterwards, not those who treated the dosing day as the intervention in itself.

When PTSD and Addiction Are Both Present

This is the situation in which most people actually arrive at the question, and it changes the calculation.

Trauma and substance use frequently travel together, and treating either in isolation tends to be where conventional pathways struggle: a person stabilises the substance use and the trauma symptoms surface, or addresses the trauma while the substance use undermines it. Ibogaine’s interest to researchers lies partly in acting on both at once, and the opioid-dependence evidence is somewhat stronger than the PTSD evidence, though it carries the same design limitations.

If this describes you, the practical implication is that the substance-use side usually has to be planned for first regardless of direction — screening, any necessary taper, and what happens in the weeks afterwards. Our comparison of ibogaine and Suboxone for opioid addiction covers the sequencing questions in more detail, including why coming off buprenorphine is its own project.

Screening Matters More Here, Not Less

Psychiatric history is a central part of ibogaine screening, and PTSD sits alongside several conditions that clinics assess carefully. A personal or family history of psychosis or bipolar disorder, active suicidality, and current unmanaged psychiatric crisis are all things a responsible clinic will ask about and may decline on. Several psychiatric medications — including some commonly prescribed for PTSD — also require review well in advance.

Do not manage this by omission. The screening exists to identify who should not proceed, and the only person harmed by an incomplete history is you. If you are concerned that disclosing something will rule you out, raise it directly with the clinician; there is often a path that involves timing or preparation rather than a flat no.

How rigorously a clinic screens is also the clearest available proxy for how it will behave on the day. Our guide to choosing a safe ibogaine clinic sets out what a thorough intake covers and what the absence of one tells you.

If You Are Considering This

A few things are worth doing before any decision, and none of them commit you to anything.

Establish what you have actually tried, and for how long. Trauma-focused therapy that was started and abandoned is not the same as trauma-focused therapy that did not work, and the distinction changes what a reasonable next step looks like.

Find out where you stand medically. A current medication list and a conversation with your own doctor will tell you quickly whether there is an obvious obstacle, and it costs nothing.

Arrange the support for afterwards before you go, not once you are back. This is the single most consistent difference between people who describe a lasting change and people who describe a remarkable week.

And check the legal position for wherever you are considering travelling, because it is widely misreported and it is not always what a provider tells you — our legal status tracker is kept to primary sources for that reason.